9VV1
Crystal structure of EGFR kinase (C797S) in complex with LN-B72
This is a non-PDB format compatible entry.
Summary for 9VV1
| Entry DOI | 10.2210/pdb9vv1/pdb |
| Descriptor | Epidermal growth factor receptor, (4-fluorophenyl)-[4-[[4-(hydroxymethyl)cyclohexyl]amino]-2-[[4-(4-methylpiperazin-1-yl)phenyl]amino]-7~{H}-pyrrolo[2,3-d]pyrimidin-5-yl]methanone, 1,2-ETHANEDIOL, ... (4 entities in total) |
| Functional Keywords | inhibitor, signaling protein |
| Biological source | Homo sapiens (human) |
| Total number of polymer chains | 1 |
| Total formula weight | 38239.19 |
| Authors | |
| Primary citation | Zhang, H.,Lan, T.,Li, R.,Li, G.,Yuan, J.,Wang, S.,Zhang, Z.,Zhang, Z.,Liu, J.,Liu, H.,Xu, L.,Li, Y.,Pan, S.,Pan, L.,Wang, X.,Wang, X.,Xu, X.,Xiao, H.,Wen, Y.,Wang, E.,Zhao, T.,Sun, J.,Wang, P.,Qiu, R.,Li, T.,Yao, J.,Liu, Z.,Zhang, G. Design, synthesis and biological evaluation of 2,4,5-trisubstituted 7H-Pyrrolo[2,3-d]pyrimidine derivatives as potent EGFR tyrosine kinase inhibitors against the C797S acquired resistance mutation. Bioorg.Med.Chem., 139:118679-118679, 2026 Cited by PubMed Abstract: The C797S mutation in the epidermal growth factor receptor (EGFR) presents a significant challenge in treating non-small cell lung cancer (NSCLC), as it confers resistance to osimertinib. To tackle this issue, we designed and synthesized novel 7H-pyrrolo[2,3-d]pyrimidine derivatives that bind to the EGFR kinase domain in the presence of the C797S mutation. The representative compound cis-32 (LN-B72) not only showed remarkable kinase inhibitory activity against EGFR and EGFR mutants, with IC values of 8.7 nM and 7.9 nM, respectively, but also displayed potent antiproliferative activity, achieving IC values of 0.046 μM and 0.060 μM in corresponding mutant cell models. Furthermore, LN-B72 exhibited broad-spectrum inhibitory activity against EGFR mutants, including those harboring Exon 20 insertion mutations. Mechanistic studies indicated that LN-B72 disrupted the EGFR signaling pathway by preventing the phosphorylation of key downstream proteins. In vivo antitumor activity studies demonstrated that LN-B72 significantly inhibited tumor growth. This work establishes a promising foundation for developing novel therapeutic strategies targeting NSCLC patients with the C797S mutation. PubMed: 42070540DOI: 10.1016/j.bmc.2026.118679 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.95 Å) |
Structure validation
Download full validation report
